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DObjective: Reoperative aortic valve replacement (re-AVR) in octogenarians is considered high risk and there-
fore might be indicated for transcatheter AVR. The minimally invasive technique for re-AVR limits dissection
and might benefit this patient population. We report the outcomes of re-AVR in high-risk octogenarians who
might be considered candidates for transcatheter AVR to assess the safety of re-AVR and minimally invasive
operative techniques.
Methods:We identified 105 patients, aged80 years, who underwent open re-AVR at our institution from July
1997 to December 2011. Patients requiring concomitant coronary bypass surgery and/or other valve surgery
were excluded. The outcomes of interest included operativemortality, postoperative complications, andmidterm
postoperative survival.
Results: Of the 105 patients, 51 underwent minimally re-AVR through upper hemisternotomy (Mre-AVR) and
54 standard full sternotomy (Fre-AVR). The mean patient age was 82.8  3.8 years. No significant differences
were found in the patient risk factors. Postoperatively, 6 patients (5.7%) underwent reoperation for bleeding, 4
(3.8%) experienced permanent stroke, 4 (3.8%) developed new renal failure, and 22 (21.0%) had new-onset
atrial fibrillation. Overall, the operative mortality was 6.7%, and the 1- and 5-year survival was 87% and
53%, respectively. When Mre-AVR and Fre-AVR were compared, the operative mortality was 9.2% in the
Fre-AVR group and 3.9% in the Mre-AVR group (P ¼ .438). Kaplan-Meier analysis showed a survival benefit
at both 1 year (79%  11.7% vs 92%  7.8%) and 5 years (38%  17.6% vs 65%  15.7%, P ¼ .028)
favoring Mre-AVR. Cox regression analysis identified heparin-induced thrombocytopenia, reoperation for
bleeding, older age, full sternotomy, and an infectious complication as predictors of mortality.
Conclusions: Octogenarians who undergo re-AVR are thought to be high-risk surgical candidates. The present
single-center series revealed acceptable in-hospital outcomes and operative mortality. Mre-AVR was associated
with better survival compared with Fre-AVR and might benefit this population. (J Thorac Cardiovasc Surg
2014;147:155-62)Reoperative aortic valve replacement (re-AVR [AVR after
previous cardiac surgery]) is increasing owing to the popu-
lation surviving after cardiac surgery and longer life expec-
tancy.1 Cardiac surgery in octogenarians and nonagenarians
is becoming more common.2 However, because of the
increased perioperative risk of morbidity and mortality
compared with that in the younger generation, the elderly
population has viewed surgical intervention as a last resort.
Re-AVR can be performed with low risk, with an operative
mortality of 4% to 7% in the present era,3,4 although data
focused on the older population are lacking. Cardiace Department of Cardiac Surgery, Brigham and Women’s Hospital, Boston,
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The Journal of Thoracic and Casurgeons are faced with the question of whether surgical
intervention will improve the outcomes in these high-risk
patients. Transcatheter AVR (TAVR) has emerged as a pro-
cedure for high-risk candidates, such as older patients
and those undergoing reoperation. Valve-in-valve (VIV)
TAVR can be performed in patients with previously placed
bioprostheses in the aortic position. It has been anticipated
that more and more patients requiring re-AVR will be
treated with TAVR in the future.
Re-AVR through a minimal access approach using upper
hemisternotomy avoids dissection of the mediastinum and
limits bleeding and blood transfusion.5 No other study has
compared the outcomes of re-AVR between a minimally
invasive technique (Mre-AVR) and standard full sternotomy
technique (Fre-AVR). TheMre-AVR approach has potential
benefit, especially for the elderly, given the limited tissue
damage and avoiding major postoperative complications.
The aim of the present study was to assess the outcome in
octogenarians undergoing re-AVR and to analyze whether
Mre-AVR will result in improved outcomes compared
with Fre-AVR as a benchmark in the upcoming era of
TAVR.rdiovascular Surgery c Volume 147, Number 1 155
Abbreviations and Acronyms
CI ¼ confidence interval
HIT ¼ heparin-induced thrombocytopenia
HR ¼ hazard ratio
LITA ¼ left internal thoracic artery
LV ¼ left ventricular
Fre-AVR ¼ standard full sternotomy reoperative
aortic valve replacement
Mre-AVR ¼ minimally invasive reoperative aortic
valve replacement
re-AVR ¼ reoperative aortic valve replacement
STS ¼ The Society of Thoracic Surgeons
TAVR ¼ transcatheter aortic valve replacement
TEE ¼ transesophageal echocardiography
VIV ¼ valve-in-valve
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Patients
We identified 105 consecutive patients aged 80 years at surgery who
had undergone isolated AVR after previous cardiac surgery from July 1997
to June 2012. Patients with concomitant coronary bypass, other valve sur-
gery, and/or aortic surgery were excluded. The institutional review board of
Brigham and Women’s Hospital approved the present study.
Contraindications and Choices
The contraindications to Mre-AVR included other concomitant cardiac
procedures, such as coronary artery bypass grafting and mitral and tricuspid
valve operations, which were excluded from the present study. No other con-
traindications were included. In our institution, the choice of the minimally
invasive approach versus full sternotomy was mainly surgeon preference.
Minimally Invasive Approach
Before the incision, all patients had had a pulmonary artery catheter with
a pacing port placed by the anesthesiologist. Also, an external defibrillator
pad was placed and transesophageal echocardiography (TEE) performed.
When peripheral cannulation was chosen, right axillary artery or
femoral artery cannulation and femoral venous cannulation were accessed.
For arterial cannulation, an 8- to 10-mm polytetrafluoroethylene graft was
sewn into the right axillary artery or femoral artery, which was connected to
an arterial circuit. For venous cannulation, a femoral venous cannula was
placed using a modified Seldinger technique, and the position was
confirmed with TEE. In all other cases, central cannulation was used after
partial sternotomy and mediastinal dissection.
Upper hemisternotomywas performed using an oscillating saw. Sternot-
omywas performed in a J-fashion to the fourth intercostal space. Cardiopul-
monary bypass was initiated in some cases before dividing the posterior
sternal table. Limited mediastinal dissection of the aorta, right atrium, and
right superior pulmonary veinwas then performed. The left internal thoracic
artery (LITA) graft was left without dissection (no dissection technique).
The proximal anastomoses of vein grafts were dissected. After dissection,
a retrograde cardioplegia catheterwas placed from the right atrial appendage
under TEE guidance, and a left ventricular (LV) vent was placed from the
aorta, right atrium, and right superior pulmonary vein, when possible.
The patient was cooled after aortic crossclamp application to prevent
ventricular fibrillation. The goal of cooling was to 28C to 32C if no
LITA graft was present and 25C to 30C if the LITAwas intact. Antegrade
and retrograde cardioplegia was given after aortic crossclamping. Direct156 The Journal of Thoracic and Cardiovascular Surgcoronary cardioplegia was given if we could not achieve retrograde access
and the left ventricle was distended owing to aortic insufficiency. Our car-
dioplegia strategy was to repeat the dose every 20 to 30 minutes and use
blood cardioplegia in all cases. LV distension was carefully monitored us-
ing TEE. The LV vent was placed from the aorta, right atrium, and right
superior pulmonary vein or through the aortic valve after aortotomy. Stan-
dard ARV was then conducted.
When cardiac activity was observed because of a patent LITA graft,
additional systemic potassium was given through the pump (40 mEq) to
a dosage of 6.0 to 7.0 mEq. Ultrafiltration was used to lower the potassium
level at the end of the case if this technique had been used. When the field
was obscured by blood return from the left coronary ostium, the pump flow
was temporarily lowered for a few seconds to place the annular sutures.
Details of the steps in patients with a patent LITA have been discussed
in our previous study.6
Defibrillation after unclamping was obtained through external pads.
De-airing was monitored using TEE, and carbon dioxide was used in the
field to limit the amount of air. Aventricular pacingwirewas placed in right
ventricular muscle if a transvenous pacing wire was unable to be inserted.
A chest tube was placed from the right pleural space, and the chest was
closed in a standard fashion.
Data Collection
The patient characteristics, medications, laboratory values, and in-
hospital outcomes of the index surgery were collected at presentation
and extracted from the hospital’s electronic medical records. The data
were coded according to The Society of Thoracic Surgeons (STS) National
Adult Cardiac Database, version 2.52, definitions, unless otherwise noted.
The primary outcomes of interest were operative mortality, frequency of
postoperative complications, and long-term survival. The postoperative
complications included cerebrovascular accident, respiratory failure, atrial
fibrillation, renal failure, and reoperation for bleeding. Cerebrovascular
accidents included strokes, transient ischemic attacks, and coma. Infectious
complications included urinary infections, pneumonia, bacteremia and/or
sepsis, deep sternal wound infections, medically managed endocarditis,
and leg infections. Infectious complicationswere confirmedby positive cul-
ture findings and collected by chart review. A composite outcome of any in-
fectious complication was also calculated. Mortality data were collected
from the hospital records, routine patient follow-up visits, our state Depart-
ment of Public Health, and query of the Social Security Death Index.
Statistical Analysis
Evaluation of dichotomous variables was done using Fisher exact
test, and the data are presented as percentages and number of cases. Contin-
uously distributed variables were evaluated using Student t test with
Levine’s homogeneity of variance. These data are presented as the mean
 standard deviation. Mann-Whitney U tests were used to evaluate non-
normally distributed continuous variables, which are presented as the
median and interquartile range. Survival was evaluated using Kaplan-
Meier analyses. The risk factors for late mortality were examined using
both univariate and multivariate Cox regression analyses; for the latter,
interaction terms were examined. Statistical analyses were performed
using the Statistical Package for Social Sciences, version 13.0 (SPSS,
Chicago, Ill), and P<.05 was considered statistically significant.
RESULTS
Study Population
From January 1997 to December 2011, 105 patients>80
years old underwent isolated re-AVR. Of these 105 patients,
54 underwent Fre-AVR and 51 underwent Mre-AVR. The
total follow-up period was 376.2 patient-years. The median
follow-up durationwas3.0 years (interquartile range, 1.2-5.3).ery c January 2014
TABLE 1. Preoperative patient characteristics
Characteristic Re-AVR at>80 y (n ¼ 105) Full sternotomy (n ¼ 54) Minimally invasive (n ¼ 51) P value
Age (y) 82.8  3.8 82.4  4.6 83.3  2.7 .270
Female gender 40.0 (42) 50.0 (27) 29.4 (15) .046
Diabetes 33.3 (35) 20.4 (11) 31.4 (16) .264
Hypercholesterolemia 84.8 (89) 87.0 (47) 82.4 (42) .592
Hypertension 83.8 (88) 81.5 (44) 86.3 (44) .600
Renal failure 4.8 (5) 7.4 (4) 2.0 (1) .364
Preoperative creatinine 1.2  0.4 1.3  0.5 1.2  0.3 .510
Preoperative hematocrit (%) 36.2  4.0 36.3  4.3 36.0  3.9 .768
CVA 10.5 (11) 11.1 (6) 9.8 (5) 1.000
NYHA class III-IV 62.9 (66) 63.0 (34) 62.7 (32) 1.000
Ejection fraction (%) 55.0 (50-60) 57.0 (55-65) 55.0 (50-60) .701
Previous CABG 85.7 (90) 79.6 (43) 92.2 (47) .094
Previous valve surgery 26.7 (28) 27.8 (15) 25.5 (13) .828
Data presented as mean standard deviation, n (%), or median (interquartile range). Re-AVR, Reoperative aortic valve replacement; CVA, cerebrovascular accident; NYHA, New
York Heart Association; CABG, coronary artery bypass grafting.
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The preoperative patient characteristics are listed in
Table 1, stratified by the technique used (Fre-AVR vs
Mre-AVR). For the total cohort, the mean age was 82.8 
3.8 years, and 40.0% were women. The incidence of med-
ical comorbidities such as hypercholesterolemia (84.8%),
hypertension (83.8%), and previous cerebrovascular acci-
dent (10.5%) was high. The incidence of heart failure
symptoms was 62.9% for New York Heart Association
class III-IV, but cardiac function was preserved with a
median ejection fraction of 55.0%. Of thosewho had under-
gone previous cardiac surgery, 85.7% had undergone coro-
nary artery bypass grafting and 26.7% valve operations.
When comparing the Fre-AVR and Mre-AVR groups,
both were similar in age (82.4 vs 83.3 years; P ¼ .27).TABLE 2. Operative characteristics
Characteristic Re-AVR at>80 y (n ¼ 105) Full
Etiology
Stenosis 81.9 (86)
Insufficiency 6.7 (7)
Stenosis and insufficiency 11.4 (12)
Cannulation strategy
Aorta directly 31.4 (33)
Axillary artery 48.6 (51)
Femoral artery 20.0 (21)
Direct RA cannulation 18.1 (19)
Femoral vein 81.9 (86)
CP strategy
Antegrade CP 46.7 (49)
Antegrade and retrograde CP 53.3 (56)
Perfusion time (min) 139 (116-167)
Crossclamp time (min) 73 (61-94)
Transfused in OR 62.9 (66)
PRBC units per patient 3 (2-4)
Data presented as n (%) or median (interquartile range). Re-AVR, Reoperative aortic valve r
blood cell.
The Journal of Thoracic and CaThe Fre-AVR group had more women (50.0% vs 29.4%;
P ¼ .05). The presence of preoperative conditions such as
renal failure (7.4% vs 2.0%; P ¼ .36), hypercholesterole-
mia (87.0% vs 82.4%; P ¼ .59), diabetes (20.4% vs
31.4%; P ¼ .26), and hypertension (81.5% vs 86.3%;
P ¼ .60) was similar between the 2 groups. More patients
in the Mre-AVR group had undergone previous coronary ar-
tery bypass grafting (79.6% vs 92.2%; P ¼ .09). Finally,
75.9% of the Fre-AVR group (41 of 54) and 80.4% of the
Mre-AVR group (41 of 51) had undergone preoperative
computed tomography.
Operative Data
The patients’ operative characteristics are summarized in
Table 2. Of the total cohort, 81.9% underwent reoperationsternotomy (n ¼ 54) Minimally invasive (n ¼ 51) P value
85.2 (46) 78.4 (40) .450
7.4 (4) 5.9 (3) 1.000
7.4 (4) 15.7 (8) .223
50 (27) 11.8 (6) .001
31.5 (17) 66.6 (34) .001
18.5 (10) 21.6 (11) .809
29.6 (16) 5.9 (3) .002
70.4 (38) 94.1 (48) .002
22.2 (12) 72.5 (37) .001
77.8 (42) 27.4 (14) .001
142 (115-165) 139 (125-180) .936
75 (63-93) 73 (62-92) .240
70.4 (38) 54.9 (28) .111
3 (2-4) 2 (2-3) .321
eplacement; RA, right atrial; CP, cardioplegia;OR, operating room; PRBC, packed red
rdiovascular Surgery c Volume 147, Number 1 157
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stenosis and insufficiency. Also, 31.4% underwent central
cannulation and 68.6% peripheral cannulation. Finally,
62.9% required transfusion in the operating room, with a
median number of 3 packed red blood cell transfusions.
Both groups had a similar incidence of aortic stenosis
(85.2% vs 78.4%;P¼ .45) and stenosis and/or insufficiency
(7.4% vs 15.7%; P ¼ .22). In the Mre-AVR group, more
peripheral cannulationwas used, especially axillary cannula-
tion (31.5% vs 66.6%; P  .001), and less central cannula-
tion (50% vs 11.8%; P  .001). More direct right atrial
cannulations were performed in the Fre-AVR group
(29.6% vs 5.9%,P¼ .002) andmore femoral venous cannu-
lations were performed in the Mre-AVR group (94.1% vs
70.4%;P¼ .002).Mre-AVRusedmore antegrade cardiople-
gia alone (72.5% vs 22.2%; P ¼ .001) and Fre-AVR used
more antegrade and retrograde cardioplegia (77.8% vs
27.5%; P ¼ .001). The 2 groups had no difference in perfu-
sion time (Fre-AVR, 142minutes vsMre-AVR, 139minutes;
P¼ .96) or crossclamp time (75 vs 73minutes;P¼ .23). The
Mre-AVR group had a trend toward fewer transfusions in the
operating room (70.4% vs 54.9%; P ¼ .11).
Operative Morbidity and Mortality
The operative morbidity and mortality is summarized in
Table 3. For the total cohort, the operative mortality was
6.7%. Also, 5.7% underwent reoperation for bleeding,
3.8% experienced permanent stroke, and 21% had new-
onset atrial fibrillation. Combined infectious complications
included urinary tract infection, pneumonia, endocarditis,
and bacteremia or sepsis; overall 30.5% had 1 infectious
complication. The median intensive care unit stay was 73.0TABLE 3. Postoperative outcomes
Outcome Re-AVR at>80 y (n ¼ 105) Full st
Reoperation for bleeding 5.7 (6)
Permanent stroke 3.8 (4)
New-onset renal failure 3.8 (4)
New-onset AF 21.0 (22) 2
HIT 3.8 (4)
Infectious complications 30.5 (32) 3
UTI 26.7 (28) 2
Pneumonia 5.7 (6)
Postoperative endocarditis 1.0 (1)
Bacteremia and/or sepsis 2.0 (2)
Transfused postoperatively 61.0 (64) 5
RBC units per patient 3.0 (2-4)
FFP transfusion 39.0 (41) 4
Platelet transfusion 38.1 (40) 4
Ventilation time (h) 11.2 (7-20) 1
ICU stay (h) 73.0 (42-121) 7
Postoperative LOS (d) 8.0 (7-12)
Operative mortality (%) 6.7 (7)
Data presented as n (%) or median (interquartile range), or median (n). Re-AVR, Reoperat
topenia; UTI, urinary tract infection; RBC, red blood cell; FFP, fresh frozen plasma; ICU
158 The Journal of Thoracic and Cardiovascular Surghours, and the median length of stay in the hospital was 8.0
days.
Cannulation-related morbidity occurred as follows: 4 of
86 patients (4.7%) developed a venous complication (3 in
the Fre-AVR and 1 in the Mre-AVR group); 3 developed
deep vein thrombosis, and 1 developed a retroperitoneal he-
matoma requiring surgery. One patient had a pseudoaneur-
ysm after femoral artery cannulation that required
intervention. The source of bleeding for reoperations were
diffuse oozing (no source) in 1 and aortotomy in 1 patient
in the Fre-AVR group and sternal wires in 3 patients and
diffuse oozing in 1 patient in the Mre-AVR group. Stroke
occurred mainly in the patients who had undergone femoral
artery cannulation (3 of 4), with fewer occurring in those
who had undergone axillary artery cannulation (1 of 4).
Heparin-induced thrombocytopenia (HIT) was seen in 4
patients. The incidence of HIT did not differ between the
Fre-AVR and Mre-AVR groups. HIT occurred within post-
operative day 3 to 7 (median, 5.5). No cases of preoperative
HIT occurred. One patient developed HIT thrombosis, re-
sulting in renal failure, which led to multiorgan failure
and death in the Mre-AVR group.
Operative mortality was statistically similar between the
2 groups (Fre-AVR, 9.3% vs Mre-AVR, 3.9%; P ¼ .44).
The Mre-AVR group showed a trend toward fewer cases
of new-onset renal failure (7.4% vs 0.0%; P ¼ .12) and
fewer cases of new-onset atrial fibrillation (28.7% vs
15.7%; P ¼ .16). Infectious complications (33.3% vs
27.5%; P ¼ .53), reoperation for bleeding (3.7% vs
7.8%; P ¼ .42), and permanent stroke (1.9% vs 5.9%;
P ¼ .35) were similar between the 2 groups. The Fre-
AVR group had a greater incidence of fresh frozen plasmaernotomy (n ¼ 54) Minimally invasive (n ¼ 51) P value
3.7 (2) 7.8 (4) .428
1.9 (1) 5.9 (3) .354
7.4 (4) 0.0 (0) .118
8.7 (15) 15.7 (8) .161
3.7 (2) 3.9 (2) 1.000
3.3 (18) 27.5 (14) .533
7.8 (15) 25.5 (13) .828
3.7 (2) 7.8 (4) .428
1.9 (1) 0.0 (0) 1.000
1.9 (1) 2.0 (1) 1.000
9.3 (32) 62.7 (32) .307
3.0 (1-4) 3.0 (2-4) .233
8.1 (26) 29.8 (15) .071
0.7 (22) 35.3 (18) .688
0.8 (7.1-19.8) 13.1 (7.2-22.9) .617
3.0 (45-121) 73.0 (33-129) .860
8.0 (7-12) 9.0 (7-15) .108
9.3 (5) 3.9 (2) .438
ive aortic valve replacement; AF, atrial fibrillation; HIT, heparin-induced thrombocy-
, intensive care unit; LOS, length of stay.
ery c January 2014
FIGURE 1. Survival analysis between full sternotomy group and minimally invasive group. AVR, Aortic valve replacement; re-AVR, reoperative aortic
valve replacement.
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dence of packed red blood cell transfusions (median, 3 U vs
3 U; P ¼ 1.0), platelet transfusions (40.7% vs 35.3%;
P ¼ .688), and overall postoperative transfusions (59.3%
vs 62.7%; P ¼ .307). The postoperative intensive care
unit stay and length of stay were similar between the 2
groups.Disposition and Readmission
No difference was found in the discharge locations. Of
the 105 patients, 49 were alive at discharge. Of these pa-
tients, 28 in the Fre-AVR group and 29 in the Mre-AVR
were discharged to a rehabilitation facility (P ¼ 1.0) and
21 patients in the Fre-AVR group and 20 patients in the
Mre-AVR group were discharged to home (P ¼ 1.0). The
readmission rates were similar (14.3% for Fre-AVR and
16.7% for Mre-AVR; P ¼ .785).The Journal of Thoracic and CaSurvival Analysis
Figure 1 shows the Kaplan-Meier analysis of survival
through 5 years. After that, the patients at risk in the Fre-
AVR group had decreased below a number amenable to
meaningful analysis.
The analysis showed overall survival at 1 year of 87% and
at 5 years of 53%. TheMre-AVRgroup had significant better
survival statistically compared with the Fre-AVR both at 1
(79% vs 92%;P¼ .03) and 5 (38% vs 65%;P¼ .03) years.
The median survival duration was 65.3 months (95% confi-
dence interval [CI], 43.2-77.2) overall and 52.0 months
(95% CI, 29.1-74.9) in the Fre-AVR group and 81.2
months (95% CI, 60.7-105.3) in the Mre-AVR group.Multivariate Analysis
Because our patients were not randomized, we sought to
examine the contributors to long-term mortality usingrdiovascular Surgery c Volume 147, Number 1 159
TABLE 4. Cox regression analysis: predictors of mortality in the
elderly
Variable P value HR 95% CI
HIT .001 9.801 2.397-40.071
Reoperation for bleeding .001 7.983 2.666-23.904
Older age (>80 y) .002 1.150 1.052-1.256
Full sternotomy .017 2.162 1.149-4.071
Any postoperative infection .026 2.158 1.096-4.251
HR, Hazard ratio; CI, confidence interval; HIT, heparin-induced thrombocytopenia.
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Table 1 that were significantly different statistically and
those deemed clinically important in an initial forward-
stepwise Cox regression analysis. Significant contributors
were then evaluated using the enter-method analysis to
address overfitting concerns. A total of 52 mortality events
occurred during the study observation period.
The significant contributors in the final model are listed
in Table 4. In order of significance, HIT (hazard ratio
[HR], 9.80; 95% CI, 2.40-40.07; P  .001), reoperation
for bleeding (HR, 7.98; 95% CI, 2.67-23.90; P  .001),
full sternotomy (HR, 2.16; 95% CI, 1.15-4.07; P¼ .02), in-
fectious complication (HR, 2.16; 95% CI, 1.10-4.25;
P ¼ .03), and increasing age (HR, 1.15; 95% CI, 1.05-
1.26; P ¼ .002) were all significantly predictive of
decreased postoperative survival. Nevertheless, survival
for the Mre-AVR group was significantly longer (P 
.001) than that for the Fre-AVR group (Figure 2).DISCUSSION
Cardiac surgery performed in octogenarians has been
becoming more common, and this trend is expected to
continue, because the elderly population is the fastest
growing population in the United States. AlthoughFIGURE 2. Cox regression analysis for predictors of mortality. AVR,
Aortic valve replacement.
160 The Journal of Thoracic and Cardiovascular Surgconsidered high risk, cardiac surgery for octogenarians
can be performed safely. A low operative mortality of 4%
to 8% and 5-year survival of 50% has been reported in cur-
rent studies for patients aged>80 years.7-9 Despite these
data, the elderly have generally not been considered ideal
candidates for cardiac surgery. In 1 study, as many as
40% of patients aged >70 years were denied cardiac
surgery because of their age.10
Reoperation cardiac surgery in this age group imposes a
greater risk, making the decision evenmore difficult for sur-
geons. In the general population, re-AVR has been shown to
have good outcomes, with an operative mortality of 5% to
7% in recent reports.3,6 Few data exist for re-AVR in older
patients. Limited published data have shown high hospital
mortality (12%-16.4%) and a 5-year survival of 50% to
60% in the elderly population.11,12 This has resulted in
greater enthusiasm for the later discussed TAVR procedure.
In the present report, we assessed the outcomes for 105
octogenarians who had undergone re-AVR. The outcomes
showed that this operation can be performed safely, with
an operative mortality of 6.7% and 1- and 5-year survival
of 87% and 53%, respectively. Our operative mortality
was low compared with the published data and was compa-
rable to the re-AVR risk in the general population.
Mre-AVR has been reported with good outcomes. Both
the right minithoracotomy approach13,14 and the partial
upper hemisternotomy approach5,15,16 have been used for
minimally invasive procedures. The benefits of Mre-AVR
have included more patients discharged to home, a shorter
length of stay,13,14,17 less pain,18 a shorter ventilation
duration,13,18 and less blood loss and transfusion
requirements compared with Fre-AVR.13,15,18 Few studies
have shown decreased operative mortality after re-AVR
using a minimally invasive technique.13,14 Sharony and
colleagues14 compared 161 (61 aortic and 100 mitral) cases
of minimally invasive right thoracotomy reoperation with
337 (160 aortic, 177 mitral) cases of full sternotomy. In their
report, the minimally invasive group had lower operative
mortality (5.6% vs 11.3%; P ¼ .04) and lower long-term
mortality, with a follow-up of 24 months.14
The population that could benefit the most from mini-
mally invasive techniques would be the elderly population,
because these techniques create less tissue trauma and do
not result in complications. ElBardissi and colleagues19 re-
ported on 249 octogenarians who had undergone minimally
invasive primary AVR. They reported an operative mortal-
ity of 3%, significantly lower than the calculated median
EuroSCORE (11%) and STS score (10.5%). The Euro-
SCORE and STS risk scores have had a poor correlation
in the elderly. No study has compared the benefit of Mre-
AVR in the elderly population.
Although not statistically significant, the Mre-AVR
group had trends toward fewer cases of new-onset renal fail-
ure and new-onset atrial fibrillation and fewer intraoperativeery c January 2014
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efits seen in other studies, such as a shorter hospital stay and
intensive care unit stay and fewer postoperative transfusions
were not observed in the present study.
Perioperative strokes, respiratory failure, and renal fail-
ure are known risks associated with operative mortality
and survival in octogenarians.6,19,20 Very elderly patients
will have reduced biologic reserves and will therefore be
more vulnerable to the deleterious effects of postoperative
complications. Preventing and minimizing postoperative
complications using methods such as early extubation and
ambulation and aspiration precautions are particularly
important for these patients. Other measures such as
maintaining an adequate fluid balance, avoiding
overdiuresis, and minimizing the use of nephrotoxic drugs
are important for preventing renal failure. Fewer
postoperative infections can be achieved by the adequate
use of antibiotics, early removal of the urinary catheter,
and early ambulation.
Three Mre-AVR patients experienced a postoperative
stroke, likely attributable to peripheral cannulation; 75%
of strokes in our patients were from femoral artery cannula-
tion. We began performing Mre-AVR in 1996, and the
initial cases were all performed using peripheral cannula-
tion. With more strokes seen with femoral artery cannula-
tion, our current practice has been to selectively perform
peripheral cannulation (axillary artery preferably) in
high-risk cases and central cannulation in low-risk cases.
Preoperative evaluation using 3-dimentional computed to-
mography will allow the surgeons to assess the relationship
between the sternum and aorta and has aided this decision-
making process. In some cases, such as coronary grafts
traversing the lower sternum or ventricle attached to the
lower sternum, the minimally invasive technique was cho-
sen to avoid injury.
The Mre-AVR group had excellent operative mortality at
3.9%. Evaluating long-term survival, statistically signifi-
cant improvements in both 1- and 5-year survival (92%
and 65%, respectively) were seen for the Mre-AVR group
compared with the conventional Fre-AVR group.
Cox regression analysis of long-tem survival showed that
the significant predictors of long-term survival included
HIT, increasing age, reoperation for bleeding, full sternot-
omy, and postoperative infectious complications. Of these,
HIT had the greatest HR. HIT is a known serious complica-
tion of cardiac surgery,21 and our study results emphasize
the importance of active investigation and early interven-
tion to minimize harm and improve the outcomes after HIT.
The indication for reoperation for bleeding in the Mre-
AVR patients was mainly bleeding from sternal wires
(75%), possibly owing to the decreased visualization of
the wire sites during sternal closure using this approach.
This likely contributed to the somewhat greater postopera-
tive transfusion needs in these patients, which might haveThe Journal of Thoracic and Cabeen the reason the Mre-AVR group did not show a benefit
in postoperative bleeding. Reoperation for bleeding was 1
of the predictors of mortality, and surgeons must pay careful
attention to prevent this problem.
The full sternotomy procedure was a predictor of mortal-
ity, indicating that a minimally invasive approach could
benefit postoperative survival in this population. The Mre-
AVR group experienced fewer events of new-onset renal
failure, new-onset atrial fibrillation, and infectious compli-
cations postoperatively. Although these differences be-
tween the 2 groups were not statistically significant, each
of these events will be more serious in the very elderly
than in younger patients. It is likely that the physiologic
sequelae from such events will shorten postoperative sur-
vival in this population. With a lower cumulative rate of
such events, postoperative survival can be maximized in
Mre-AVR patients.
TAVR has emerged as 1 of the innovative and most antic-
ipated treatments for high-risk surgical patients such as
older patients. For primary AVR in high-risk patients, the
Placement of Aortic Transcatheter Valve (PARTNER) trial
showed that TAVR had outcomes equivalent to those of sur-
gical AVR for 2 years.22,23 The perioperative mortality
was 3.4% after TAVR in a group of patients with an STS-
predicted mortality estimated at>10%. However, TAVR
is not risk-free. More paravalvular leaks (7% rate at 1
year ofmoderate to severe paravalvular leaks) have occurred
with TAVR compared with surgical intervention and was
directly associated with mortality.23 If a bioprosthetic valve
is present, TAVR can be used to perform a VIV technique. In
the largest review of 202 patients undergoing VIV TAVR,
the 30-day mortality was 8.4% and the calculated 1-year
survival was 85.8%.24 Although promising outcomes have
been reported, coronary ostial obstruction and a persistent
gradient remain problems for VIV TAVR.
The future identification of a high-risk group for TAVR
could allow us to tailor patient treatment, and minimally
invasive techniques will likely have a significant role by
providing good outcomes after re-AVR in octogenarians.
Study Limitations
This was a single-institution, observational cohort study
and was subject to all the limitations inherent in such a
design. Generalizing our findings to the larger population
of octogenarian aortic valve patients should be done with
caution. Because the patients were not randomly assigned
to treatment, selection biases we could not control for could
have contributed to our findings. Propensity matching anal-
ysis is another method to limit the bias; however, propensity
matching would decrease the number of patients in each
arm, which would not result in any meaningful statistical
conclusion. Therefore, we did not perform such an analysis.
The absolute numbers of the present study were low; thus,
we lacked the power to detect statistically significantrdiovascular Surgery c Volume 147, Number 1 161
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Ddifferences between the 2 groups for low frequency events
such as operative mortality. Also, because multiple sur-
geons performed the procedures, a possibility exists for
selection bias by surgeon.
CONCLUSIONS
Re-AVR can be performed safely even in octogenarians,
with a similar risk to that of the general population. A mini-
mally invasive technique can improve the outcomes in this
population by minimizing trauma and preventing postoper-
ative complications. This could be a valuable option for
patients requiring re-AVR.References
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